In a filing, Roivant Sciences Ltd revealed its President & COO Venker Eric unloaded Company’s shares for reported $1.06 million on Feb 20 ’25. In the deal valued at $10.65 per share,100,000 shares were sold. As a result of this transaction, Venker Eric now holds 896,869 shares worth roughly $9.44 million.
Then, Venker Eric bought 100,000 shares, generating $1,065,022 in total proceeds.
Before that, Kumar Rakhi sold 227,500 shares. Roivant Sciences Ltd shares valued at $2,372,825 were divested by the Chief Accounting Officer at a price of $10.43 per share. As a result of the transaction, Kumar Rakhi now holds 163,264 shares, worth roughly $1.72 million.
Wolfe Research initiated its Roivant Sciences Ltd [ROIV] rating to an Outperform in a research note published on February 15, 2024; the price target was $17. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early January with a ‘”an Overweight”‘ rating. Deutsche Bank began covering ROIV with “Buy” recommendation on December 12, 2023. Guggenheim started covering the stock on October 17, 2023. It rated ROIV as “a Buy”.
Price Performance Review of ROIV
On Friday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock fall -1.50% to $10.52. Over the last five days, the stock has lost -0.38%. Roivant Sciences Ltd shares have fallen nearly -11.07% since the year began. Nevertheless, the stocks have fallen -8.84% over the past one year. While a 52-week high of $13.06 was reached on 01/02/25, a 52-week low of $9.76 was recorded on 02/13/25. SMA at 50 days reached $11.24, while 200 days put it at $11.36.
Levels Of Support And Resistance For ROIV Stock
The 24-hour chart illustrates a support level at 10.43, which if violated will result in even more drops to 10.35. On the upside, there is a resistance level at 10.66. A further resistance level may holdings at 10.81. The Relative Strength Index (RSI) on the 14-day chart is 38.62, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.04, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.54%. Stochastics %K at 26.58% indicates the stock is a holding.
The most recent change occurred on June 08, 2023 when BofA Securities began covering the stock and recommended ‘”a Neutral”‘ rating along with a $10.50 price target.
